Classifications: analgesic, nonsteroidal antiinflammatory drug (nsaid); antipyretic; Therapeutic: nsaid, analgesic; antirheumatic; antipyretic
Pregnancy Category: C
600 mg tablet
Long-acting NSAID agent, which is an effective prostaglandin synthetase inhibitor. It inhibits COX-1 and COX-2 enzymes needed
for prostaglandin synthesis at the site of inflammation.
Has antiinflammatory, antipyretic, and analgesic properties.
Treatment of osteoarthritis and rheumatoid arthritis.
Ankylosing spondylitis, chronic pain, gout, oral surgery pain, temporal arteritis, tendinitis.
Hypersensitivity to oxaprozin or any other NSAID; complete or partial syndrome of nasal polyps; angioedema; CABG perioperative
pain; pregnancy (category C) in first and second trimesters, and pregnancy (category D) in third trimester; lactation.
History of GI bleeding, alcoholism, smoking; history of severe hepatic dysfunction, renal insufficiency; cardiac disease;
coagulopathy; photosensitivity; older adults. Safety and effectiveness in children <6 y are not established.
Route & Dosage
|Osteoarthritis, Rheumatoid Arthritis
Adult: PO 6001200 mg q.d. (max: 1800 mg/d or 25 mg/kg, whichever is lower)
- Give with meals or milk to decrease GI distress.
- Divide doses in those unable to tolerate once-daily dosing.
- Use lower starting doses for those with renal or hepatic dysfunction, advanced age, low body weight, or a predisposition
to GI ulceration.
Adverse Effects (≥1%)CNS:
Tinnitus, headache, insomnia
, somnolence. GI:
Diarrhea, abdominal pain, nausea, dyspepsia, flatulence, melena, ulcers, constipation
, dry mouth, gastritis
Rash, pruritus. Urogenital:
Dysuria, urinary frequency.
Diagnostic Test Interference
May cause false-positive reactions for benzodiazepines with urine drug-screening tests.
May attenuate the antihypertensive response to diuretics
s increase the risk of methotrexate
toxicity. May increase aspirin
toxicity. Herbal: Feverfew, garlic, ginger, ginkgo
may increase risk of bleeding.
Readily from GI tract. Peak:
125 min. Onset:
16 wk for maximum therapeutic effect. Distribution:
99% protein bound. Distributes into synovial fluid, crosses placenta. Distributed into breast milk. Metabolism:
In the liver. Elimination:
60% in urine, 3035% in feces. Half-Life:
Assessment & Drug Effects
- Monitor for S&S of GI bleeding, especially in patients with a history of inflammation or ulceration of upper GI tract, or
those treated chronically with NSAIDs.
- Monitor patients with CHF for increased fluid retention and edema. Report rapid weight increases accompanied by edema.
- Lab tests: Perform baseline and periodic evaluation of Hgb, kidney and liver function. Auditory and ophthalmologic exams
are recommended with prolonged or high-dose therapy.
Patient & Family Education
- Be aware that alcoholism and smoking increase risk of GI ulceration.
- Report immediately dark tarry stools, "coffee ground" or bloody emesis, or other GI distress.
- Avoid aspirin or other NSAIDs without explicit permission of physician.
- Be aware of the possibility of photosensitivity, which results in a rash on sun-exposed skin.
- Report immediately to physician ringing in ears, decreased hearing, or blurred vision.
- Do not exceed ordered dose. The goal of therapy is lowest effective dose.